Showing results (21-30 of 2,196) with videos related to
Sort By:
Pageof 220
Southern Medical Journal|May 1, 1993
Ondansetron: a novel antiemetic agentW D Figg, C L Graham, L J Hak, et al.Invasion & Metastasis|January 21, 2000
UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic responseE A Kruger, M V Blagosklonny, S C Dixon, et al.Clinical Pharmacokinetics|May 1, 1997
Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerationsS C Piscitelli, W G Reiss, W D Figg, et al.Cancer Chemotherapy and Pharmacology|June 5, 1999
Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cellsS C Dixon, E A Kruger, K S Bauer, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 6, 2001
Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanningJ A Carrasquillo, M Whatley, V Dyer, et al.Pharmacotherapy|March 20, 2001
Phenylacetate pharmacokinetics based on iterative two-stage population analysisA H Burstein, E Reed, A C Tompkins, et al.Journal of Molecular Medicine (Berlin, Germany)|July 30, 1999
The androgen receptor: genetic considerations in the development and treatment of prostate cancerK J Cude, S C Dixon, Y Guo, et al.Prostate Cancer and Prostatic Diseases|December 24, 2002
Malignant ascites as only manifestation of metastatic prostate cancerM W Saif, W D Figg, S Hewitt, et al.The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?B Rochat, J M Morsman, G I Murray, et al.The American Journal of Cardiology|November 15, 1995
Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal womenV Guetta, R M Lush, W D Figg, et al.Pageof 220